Who are Xeris Biopharma Holdings, Inc.'s main suppliers?

Xeris Biopharma Holdings, Inc. (XERS) key suppliers include: Corcept Therapeutics Incorporated, Corcept Therapeutics Incorporated, ORANY, ORANY, Teva Pharmaceutical Industries Limited and 1 more. View the full supplier network at chainsifter.com/chain/XERS.

Who are Xeris Biopharma Holdings, Inc.'s major customers?

Xeris Biopharma Holdings, Inc. (XERS) key customers include: Corcept Therapeutics Incorporated, Corcept Therapeutics Incorporated, ORANY, ORANY, Teva Pharmaceutical Industries Limited and 1 more. View the full customer network at chainsifter.com/chain/XERS.

What sector is Xeris Biopharma Holdings, Inc. in?

Xeris Biopharma Holdings, Inc. (XERS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

XERS Supply Chain: Xeris Biopharma Holdings, Inc. Supplier List & 15 Relationships

6Suppliers

6Customers

3Debt Items

20Related Chains

Xeris Biopharma Holdings, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CORT	Corcept Therapeutics Incorporated	72%	duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
CORT	Corcept Therapeutics Incorporated	72%	Reciprocal relationship from CORT graph: range of disorders, including central serous retinopathy, post-traumatic stress disorder, anxiety, alcoholism, cocaine addiction, Alzheimer’s disease, ALS, hy…
ORANY	ORANY	72%	completion of extensive preclinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including the FDA’s Good Laboratory Practice ("GLP") regulation…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from XERS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from XERS graph: completion of extensive preclinic…
TEVJF	Teva Pharmaceutical Industries Limited	72%	duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
TEVJF	Teva Pharmaceutical Industries Limited	72%	Reciprocal relationship from TEVJF graph: Reciprocal relationship from XERS graph: Reciprocal relationship from TEVJF graph: Reciprocal relationship from XERS graph: duct in Gvoke HypoPen is a propri…

Xeris Biopharma Holdings, Inc. Customers

Ticker	Name	Confidence	Evidence
CORT	Corcept Therapeutics Incorporated	72%	duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
CORT	Corcept Therapeutics Incorporated	72%	Reciprocal relationship from CORT graph: ol synthesis inhibitor osilodrostat to treat patients with Cushing’s disease, which approval was broadened in April 2025 to include adult patients with any et…
ORANY	ORANY	72%	duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from XERS graph: duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC…
TEVJF	Teva Pharmaceutical Industries Limited	72%	duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC (collectively "SHL"). SHL produces device sub-assemblies at its facility in Taiwan…
TEVJF	Teva Pharmaceutical Industries Limited	72%	Reciprocal relationship from TEVJF graph: Reciprocal relationship from XERS graph: duct in Gvoke HypoPen is a proprietary multi-product device platform developed by SHL Medical AG and SHL Pharma, LLC…

Xeris Biopharma Holdings, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
XERS-DEBT	Debt stack $258.6M	90%	Market cache reports total debt of $258.6M.
XERS-DEBT-13654	Warrants outstanding: 2275313	90%	xbrl warrant detail from xbrl 2026-01-31.
XERS-DEBT-13655	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

Xeris Biopharma Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Xeris Biopharma Holdings, Inc..

Xeris Biopharma Holdings, Inc. Ownership

Holder	Name	Confidence	Evidence
XERS-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 240 tracked holders.

Xeris Biopharma Holdings, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
TEVJF	Teva Pharmaceutical Industries Limited	100.00	1	['customer', 'supplier']
ORANY	ORANGE	100.00	1	['customer', 'supplier']
AMZE	Amaze Holdings, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
CNOB	ConnectOne Bancorp, Inc.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CHUC	Charlie's Holdings, Inc.	50.00	2
CLNE	Clean Energy Fuels Corp.	50.00	2
FENC	Fennec Pharmaceuticals Inc.	50.00	2
ALVO	Alvotech	50.00	2
EQR	Equity Residential	50.00	2
AZN	AstraZeneca PLC	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
DWTX	Dogwood Therapeutics, Inc.	50.00	2
ESS	Essex Property Trust, Inc.	50.00	2
ED	Consolidated Edison, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2

Xeris Biopharma Holdings, Inc. Supply Chain